30 closest matches · ranked by relevance
Nasopharyngeal Carcinoma
Primary: Objective Response Rate (ORR) Assess by Independent Review Committee (IRC) — 28.3 percentage of participants
Nasopharyngeal Nonkeratinizing Carcinoma · Recurrent Nasopharynx Carcinoma · Stage III Nasopharyngeal Carcinoma AJCC v7
Primary: Confirmed Response Rate (Complete Response or Partial Response) Based on RECIST Version 1.1 — 20.5 percentage of patients with a response
Recurrent or Metastatic Nasopharyngeal Cancer
Primary: Progression-free Survival as Assessed by the Independent Review Committee (IRC) — 9.2; 7.4 Months
Nasopharyngeal Carcinoma
Primary: Rate of Completion of All Adjuvant Immunotherapy — 100 percentage of participants
Nasopharyngeal Carcinoma
Primary: Progression-free Survival (PFS) as Per RECIST v 1.1 Using Central Assessment - Number of Participants With Progression or Death — 62; 32; 3; 1 Participants
Nasopharyngeal Carcinoma
Primary: Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma. — 25; 24.9 Months — p=0.1942
Nasopharyngeal Neoplasms
Primary: Overall Survival (OS) — 17.2; 15.3 Months — p=0.2262
Stage II Lymphoepithelioma of the Nasopharynx · Stage II Squamous Cell Carcinoma of the Nasopharynx · Stage III Lymphoepithelioma of the Nasopharynx
Primary: Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy — 18; 4 Participants
Nasopharyngeal Carcinoma
Primary: 3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy — 100 participants with loco-regional control
Nasopharyngeal Neoplasms
Primary: Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent…
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Recurrent or Metastatic NPC
Primary: IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 — 8.2; 21.4 months
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Nasopharyngeal Carcinoma
Primary: Positive Nasopharynx Biopsy Results Detected by NBI System in Those Post-radiotherapy 8th Week NPC Patient — 14; 1; 20; 1 participants
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Head and Neck Cancer
Primary: Patient Response — 11; 15; 6; 0 participants
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Recurrent Lymphoepithelioma of the Nasopharynx · Recurrent Squamous Cell Carcinoma of the Nasopharynx · Stage IV Lymphoepithelioma of the Nasopharynx
Primary: Clinical Benefit Rate — 54.5 percentage of participants
Recurrent Head and Neck Cancer
Primary: Safety Measures (Adverse Events and Laboratory Parameters) With Repeat Cycles of Treatment. — 5; 0; 8; 8 Participants
Nasopharyngeal Neoplasms · Carcinoma
Primary: Number of Participants With Complete Response (CR) — 1; 0 participants — p=1.0000
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 60 percentage of participants
Nasopharyngeal Cancer
Primary: Progression Free Survival. — 6.3 Months
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Primary: Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the…
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Nasopharyngeal Cancer
Primary: Comparing the Level of Urinary N-telopeptide (uNTx) in the Two Arms . — 75; 94; 29; 88 nM /mM — p=0.370